Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs.
Cosmi B, Legnani C, Pengo V, Ghirarduzzi A, Testa S, Poli D, Prisco D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Cosmi B, et al. Thromb Haemost. 2013 Mar;109(3):510-6. doi: 10.1160/TH12-01-0041. Epub 2013 Jan 10. Thromb Haemost. 2013. PMID: 23306310 Clinical Trial.
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry.
Pastori D, Antonucci E, Violi F, Palareti G, Pignatelli P; START2 Registry Investigators ‡; START2 Registry Investigators<xref ref-type="author-note" rid="jah34460-note-1002"><sup>‡</sup></xref>. Pastori D, et al. J Am Heart Assoc. 2019 Nov 5;8(21):e012596. doi: 10.1161/JAHA.119.012596. Epub 2019 Oct 28. J Am Heart Assoc. 2019. PMID: 31656119 Free PMC article.
D-dimer testing to determine the duration of anticoagulation therapy.
Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. Palareti G, et al. Among authors: tosetto a. N Engl J Med. 2006 Oct 26;355(17):1780-9. doi: 10.1056/NEJMoa054444. N Engl J Med. 2006. PMID: 17065639 Free article. Clinical Trial.
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, Mir R. Federici AB, et al. Among authors: tosetto a. Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241264541. doi: 10.1177/10760296241264541. Epub 2024 Jul 21. Clin Appl Thromb Hemost. 2024. PMID: 39033425 Free PMC article.
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M; European HAemophilia Safety Surveillance (EUHASS) participants. Fischer K, et al. Res Pract Thromb Haemost. 2024 May 27;8(4):102461. doi: 10.1016/j.rpth.2024.102461. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39026659 Free PMC article.
Can the Charlson comorbidity index help to guide DOAC dosing in patients with atrial fibrillation and improve the efficacy and safety of treatment? A subanalysis of the MAS study.
Palareti G, Legnani C, Testa S, Paoletti O, Cini M, Antonucci E, Pengo V, Poli D, Ageno W, Prandoni P, Prisco D, Tosetto A; MAS Working Group. Palareti G, et al. Among authors: tosetto a. Curr Probl Cardiol. 2025 Jan;50(1):102913. doi: 10.1016/j.cpcardiol.2024.102913. Epub 2024 Oct 30. Curr Probl Cardiol. 2025. PMID: 39481583
252 results